Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 1953-1958

  Inoue, Yasuyuki ^a   Saito, Tasuku ^a   Ogawa, Kohei ^a   Nishio, Yuji ^a   Kosugi, Shigeki ^a   Suzuki, Yoshinori ^a   Sakai, Hirotaka ^a   Kato, Masayuki ^a   Takahashi, Masatomo ^a   Miura, Ikuo ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Disseminated intravascular coagulation; Hematological malignancies; High mobility group box 1; Recombinant human thrombomodulin; Systemic inflammatory response syndrome

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; RECOMBINANT THROMBOMODULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CYTOPENIA; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REMISSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T CELL LEUKEMIA; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEMATOLOGIC NEOPLASMS; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; ROC CURVE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84882979727     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.752081     Document Type: Article

References (24)

1. J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. JImmunol 2000;165:2950-2954.
2. Yang H, Wang H, Tracey K J. HMGB1 rediscovered as a cytokine. Shock 2001;15:247-253.
3. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Th romb Haemost 2005;94:975-979.
4. Huang LF, Yao YM, Dong N, et al. Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients. Cytokine 2011;53:29-34.
5. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. JTh romb Haemost 2007;5:31-41.
6. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): Diagnostic criteria of the international society of thrombosis and hemostasis (ISTH) and of the Japanese ministry of health and welfare for overt DIC. Am J Hematol 2003;74:17-22.
7. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
8. Fukami A, Adachi H, Yamaguchi S, et al. Factors associated with serum high mobility group box 1(HMGB1) levels in general population. Metabolism 2009;58:1688-1693.
9. Abeyama K, D Stren M, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. JClin Invest 2005;115:1267-1274.
10. Meyer A, Staratschek-Jox A, Springwald A, et al. Non-Hodgkin lymphoma expressing high levels of the danger-signaling protein HMGB1. Leuk Lymphoma 2008;49:1184-1189.
11. Gibot S, Massin F, Cravoisy A, et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007;33:1347-1353.
12. Yasuda T, Ueda T, Takeyama Y, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006;33:359-363.
13. Nomura S, Fujita S, Ozasa R, et al. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. Platelets 2011;22:396-397.
14. Kang R, Tang DL, Cao LZ, et al. High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor alpha in leukemic cell. Zhonghua Er Ke Za Zhi 2007;45:329-333.
15. Liu L, Yang M, Kang R, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011;25:23-31.
16. Esmon CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746.
17. Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987;6:1981-1997.
18. Zushi M, Gomo K, Yamamoto S, et al. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989;254:10351-10353.
19. Wang H, Bloom O, Zhang M, et al. HMGB-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
20. Inoue Y, Kosugi S, Miura I, et al. Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Th romb Res 2011;127:603-604.
21. Ikezoe T, Togitani K, Komatsu N, et al. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:783-785.
22. Sakai M, Ikezoe T, Bandobashi K, et al. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:803-805.
23. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101:2654-2660.
24. Luft T, Dietrich S, Falk C, et al. Steroid-refractory CVHD:T-cell attack within a vulnerable endothelial system. Blood 2011;118:1685-1692.